| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | IC-87114 | CTRPv2 | pan-cancer | AAC | 0.027 | 0.5 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | azacitidine | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | bafilomycin A1 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.5 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | 0.022 | 0.5 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | -0.025 | 0.5 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.5 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.022 | 0.5 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | 0.04 | 0.5 |